Rangering i aksjer
#17187
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Handel Cellectis S.A. (ALCLS)
Pris ALCLS pris med markedsverdi på B
Markedsverdi av Cellectis S.A.(ALCLS)
Markedsverdi: $256.68M
Per September 2026 har Cellectis S.A. en markedsverdi på $256.68M. Dette gjør Cellectis S.A. til det 17187th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Cellectis S.A. fra 2007 til 2026
ALCLS sammenlignet med topp 5 mest populære stocks
| Pris på ALCLS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.325T
|
+2,074,279.59%
|
|
|
|
|
$4.770T
|
+1,858,181.97%
|
|
|
|
|
$4.029T
|
+1,569,738.09%
|
|
|
|
|
$3.687T
|
+1,436,157.62%
|
|
|
|
|
$2.739T
|
+1,067,096.38%
|
